CYNK-001 receives Fast Track designation from FDA for recurrent glioblastoma multiforme

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CYNK-001, a natural killer cell therapy, has received Fast Track designation from FDA for the treatment of adults with recurrent glioblastoma multiforme.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


A month after reporting to work in the top job at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Taofeek K. Owonikoko reflected on the obligations that come with being a Black director of an NCI-designated cancer center.